Home › Funds › ELKHORN PARTNERS LIMITED PARTNERSHIP › NEPH
ELKHORN PARTNERS LIMITED PARTNERSHIP position in NEPH
NEPHROS INC · Health Care
ELKHORN PARTNERS LIMITED PARTNERSHIP reported holding 11,000 shares of NEPH (NEPHROS INC) in its Q3 2026 13F filing — a position valued at US$41K, representing 0.04% of its reported portfolio and ranking #38 among its reported holdings. ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed NEPH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ELKHORN PARTNERS LIMITED PARTNERSHIP's NEPH position evolved
ELKHORN PARTNERS LIMITED PARTNERSHIP first disclosed a stake in NEPH in Q3 2023 at 45,341 shares (US$67K). The position peaked in Q4 2023 at 31,900 shares, worth US$110K. Across 13 filings, ELKHORN PARTNERS LIMITED PARTNERSHIP increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 11,000 shares valued at US$41K. Notable position changes include a 63% trim in Q2 2025 (shares rose 16% over the following quarter), a 44% trim in Q4 2025 (shares fell 39% over the following quarter), a 71% increase in Q1 2026 (shares rose 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 45.34K | $67.00K | New |
| Q4 2023 | 31.90K | $110.00K | Reduce |
| Q1 2024 | 36.00K | $79.00K | Add |
| Q2 2024 | 36.00K | $76.00K | Hold |
| Q3 2024 | 36.44K | $62.00K | Add |
| Q4 2024 | 41.43K | $61.00K | Add |
| Q1 2025 | 38.92K | $67.00K | Reduce |
| Q2 2025 | 14.50K | $59.30K | Reduce |
| Q3 2025 | 12.50K | $59.12K | Reduce |
| Q4 2025 | 7.00K | $34.16K | Reduce |
| Q1 2026 | 12.00K | $35.76K | Add |
| Q2 2026 | 11.00K | $39.27K | Reduce |
| Q3 2026 | 11.00K | $40.81K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NEPH and 13F data
NEPH (NEPHROS INC) is a Health Care company. 31 other funds we track also report a position in NEPH — the largest reported positions include WEXFORD CAPITAL LP (US$12.9M), Topline Capital Management, LLC (US$1.9M), MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US$1.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NEPH
- WEXFORD CAPITAL LP 3.60M sh · $12.85M · Q2 2026
- Topline Capital Management, LLC 535.70K sh · $1.91M · Q2 2026
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY 346.81K sh · $1.29M · Q3 2026
More on ELKHORN PARTNERS LIMITED PARTNERSHIP
FAQ
How long has ELKHORN PARTNERS LIMITED PARTNERSHIP held NEPH?
ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed NEPH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ELKHORN PARTNERS LIMITED PARTNERSHIP's current position in NEPH?
As of Q3 2026, ELKHORN PARTNERS LIMITED PARTNERSHIP holds 11.00K shares of NEPH (NEPHROS INC), valued at $40.81K, representing 0.04% of its reported portfolio and ranking #38.
Has ELKHORN PARTNERS LIMITED PARTNERSHIP been buying or selling NEPH?
In the latest 13F filing (Q3 2026), ELKHORN PARTNERS LIMITED PARTNERSHIP held unchanged its position in NEPH. The position peaked in Q4 2023 at 31.90K shares.
Which other funds hold NEPH?
Other major institutional holders of NEPH include WEXFORD CAPITAL LP, Topline Capital Management, LLC, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.